Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors. Learn how Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers.

Topics will include:

• Advantages of personalized, tumor-informed ctDNA assay for molecular residual disease detection
• Signatera clinical data in early and late stage solid tumors
• Growing site network to conduct trials with next-gen biotherapeutics
• Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout.

Join this webinar to discover the applications of Signatera™, a novel assay that detects ctDNA with high sensitivity and specificity to monitor molecular residual disease (MRD), early recurrence, and treatment response across solid tumors in clinical trials.